Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/7858
ANTI-GOLGI COMPLEX ANTIBODIES DURING PEGYLATED-INTERFERON THERAPY FOR HEPATITIS C
Autoanticorpos/sangue
Complexo de Golgi/imunologia
Hepatite C/sangue
Hepatite C/quimioterapia
Interferon-alfa/efeitos adversos
Polietilenoglicóis/efeitos adversos
Ribavirina/efeitos adversos
Alanina Transaminase/sangue
Antivirais/uso terapêutico
Progressão da Doença
Quimioterapia Combinada
Hepacivirus/genética
Interferon-alfa/uso terapêutico
Humanos
Fígado/patologia
Cirrose Hepática/patologia
Polietilenoglicóis/uso terapêutico
Masculino
Meia-Idade
Proteínas Recombinantes
Ribavirina/uso terapêutico
Autor(es)
Afiliação
Faculty of Medicine University Hospital of Bahia. Gastro-Hepatology Unit. Salvador, BA, Brasil
Federal University of Bahia. Post Graduated Program on Medicine and Health Faculty of Medicine. Salvador, BA, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Salvador, BA, Brasil
Federal University of Bahia. Post Graduated Program on Medicine and Health Faculty of Medicine. Salvador, BA, Brasil
LEME Laboratory. Salvador, BA, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Salvador, BA, Brasil
INSERM_U. University Claude Bernard. Lyon, France
Federal University of Bahia. Post Graduated Program on Medicine and Health Faculty of Medicine. Salvador, BA, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Salvador, BA, Brasil
Federal University of Bahia. Post Graduated Program on Medicine and Health Faculty of Medicine. Salvador, BA, Brasil
LEME Laboratory. Salvador, BA, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Salvador, BA, Brasil
INSERM_U. University Claude Bernard. Lyon, France
Resumo em Inglês
Background/Aim: Pegylated interferon (Peg-IFN) plus ribavirin is
the standard therapy for hepatitis C. Peg-IFN has several antiviral
mechanisms, but its role in hepatitis C treatment seems to be related to its
immunomodulatory effect. Ribavirin, an antiviral agent, potentiates IFN
activity when added to it. Both drugs are associated with adverse reactions of
different magnitudes. Autoimmune phenomena have been reported with this
treatment. In this paper, we describe cases of ALT/GGT flares during Peg-
IFN plus ribavirin treatment, which related to the appearance of anti-Golgi
antibody and disease progress. Methods: We investigated three patients with
hepatitis C and severe ALT/GGT flares during Peg-IFN and ribavirin
treatment coinciding with anti-Golgi complex antibody as the only marker of
autoimmunity. We then reviewed the medical files and tested anti-Golgi
antibody in stored sera from 25 patients treated with conventional IFN and
in 14 patients treated with Peg-IFN. Results: The three patients were male,
over 45 years of age; all were relapsers and non-responders. Anti-Golgi
antibody was positive during treatment coinciding with ALT/GGT flares but
with hepatitis C virus (HCV)-RNA negativity, disappearing after stopping
treatment, with normalization of ALT/AST levels. One patient had
progression of fibrosis from F2 to F3 despite negativity of HCV-RNA. In the
last group, only two patients treated with Peg-IFN experienced ALT/GGT
flares but without anti-Golgi antibody Conclusions: The presence of anti-
Golgi complex antibody could be a marker of a temporary autoimmune
phenomenon and progressive disease.
DeCS
Antivirais/efeitos adversosAutoanticorpos/sangue
Complexo de Golgi/imunologia
Hepatite C/sangue
Hepatite C/quimioterapia
Interferon-alfa/efeitos adversos
Polietilenoglicóis/efeitos adversos
Ribavirina/efeitos adversos
Alanina Transaminase/sangue
Antivirais/uso terapêutico
Progressão da Doença
Quimioterapia Combinada
Hepacivirus/genética
Interferon-alfa/uso terapêutico
Humanos
Fígado/patologia
Cirrose Hepática/patologia
Polietilenoglicóis/uso terapêutico
Masculino
Meia-Idade
Proteínas Recombinantes
Ribavirina/uso terapêutico
Compartilhar